Northcoast Research cut shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) from a buy rating to a neutral rating in a research report sent to investors on Tuesday.

ZBH has been the subject of a number of other research reports. Royal Bank Of Canada cut their price target on shares of Zimmer Biomet Holdings from $143.00 to $130.00 and set an outperform rating for the company in a research note on Tuesday, November 1st. RBC Capital Markets set a $143.00 price target on shares of Zimmer Biomet Holdings and gave the stock a buy rating in a research note on Wednesday, September 14th. Barclays PLC boosted their price target on shares of Zimmer Biomet Holdings from $140.00 to $145.00 and gave the stock an overweight rating in a research note on Tuesday, August 23rd. Argus reissued a buy rating and issued a $140.00 price target on shares of Zimmer Biomet Holdings in a research note on Thursday, September 22nd. Finally, JMP Securities upped their price objective on shares of Zimmer Biomet Holdings from $131.00 to $145.00 and gave the company a market outperform rating in a research note on Friday, July 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $131.15.

Zimmer Biomet Holdings (NYSE:ZBH) opened at 100.68 on Tuesday. The company’s 50-day moving average is $122.08 and its 200-day moving average is $122.84. Zimmer Biomet Holdings has a 52 week low of $88.27 and a 52 week high of $133.21. The company has a market cap of $20.15 billion, a P/E ratio of 56.37 and a beta of 1.28.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings results on Monday, October 31st. The company reported $1.79 EPS for the quarter, hitting the Zacks’ consensus estimate of $1.79. Zimmer Biomet Holdings had a net margin of 3.46% and a return on equity of 16.48%. The business earned $1.83 billion during the quarter, compared to analysts’ expectations of $950.20 million. During the same quarter in the previous year, the company earned $1.64 EPS. The business’s quarterly revenue was up 4.0% compared to the same quarter last year. On average, analysts anticipate that Zimmer Biomet Holdings will post $7.92 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 28th. Stockholders of record on Friday, September 23rd were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.95%. The ex-dividend date was Wednesday, September 21st. Zimmer Biomet Holdings’s payout ratio is currently 75.00%.

In other news, insider Stuart G. Kleopfer sold 3,397 shares of Zimmer Biomet Holdings stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $129.71, for a total transaction of $440,624.87. Following the sale, the insider now owns 3,000 shares in the company, valued at $389,130. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Daniel E. Williamson sold 2,716 shares of Zimmer Biomet Holdings stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $129.96, for a total transaction of $352,971.36. Following the sale, the insider now owns 2,000 shares in the company, valued at approximately $259,920. The disclosure for this sale can be found here. Insiders own 1.22% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. Liberty Capital Management Inc. bought a new stake in Zimmer Biomet Holdings during the third quarter valued at about $108,000. Tower Research Capital LLC TRC boosted its stake in Zimmer Biomet Holdings by 205.3% in the second quarter. Tower Research Capital LLC TRC now owns 916 shares of the company’s stock valued at $110,000 after buying an additional 616 shares during the last quarter. NEXT Financial Group Inc boosted its stake in Zimmer Biomet Holdings by 64.5% in the third quarter. NEXT Financial Group Inc now owns 913 shares of the company’s stock valued at $119,000 after buying an additional 358 shares during the last quarter. Global X Management Co. LLC boosted its stake in Zimmer Biomet Holdings by 238.4% in the second quarter. Global X Management Co. LLC now owns 1,032 shares of the company’s stock valued at $124,000 after buying an additional 727 shares during the last quarter. Finally, Parkside Financial Bank & Trust boosted its stake in Zimmer Biomet Holdings by 0.5% in the third quarter. Parkside Financial Bank & Trust now owns 964 shares of the company’s stock valued at $125,000 after buying an additional 5 shares during the last quarter. Hedge funds and other institutional investors own 88.66% of the company’s stock.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.